Brentuximab vedotin
- Generic Name
- Brentuximab vedotin
- Brand Names
- Adcetris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 914088-09-8
- Unique Ingredient Identifier
- 7XL5ISS668
- Background
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug labe...
- Indication
Brentuximab vedotin is indicated in adult patients for the treatment of previously untreated stage III or IV classical Hodgkin's lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine. It is also indicated for the treatment of cHL post-autologous hematopoietic stem cell transplantation (auto-HSCT) in patients at high risk of relapse or ...
- Associated Conditions
- CD30-expressing Mycosis Fungoides (MF), Classical Hodgkin's Lymphoma, Peripheral T-Cell Lymphoma (PTCL), Primary Cutaneous Anaplastic Large Cell Lymphoma, Systemic Anaplastic Large Cell Lymphoma, Stage 3 Classical Hodgkin's Lymphoma
- Associated Therapies
- -
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- University College, London
- Target Recruit Count
- 1042
- Registration Number
- NCT04685616
- Locations
- 🇳🇱
Reinier de Graafweg 3-11 - Postbus 5011 - 2625 AD Delft, Delft, Netherlands
🇬🇧Colchester Hospital, ESNEFT, Colchester, United Kingdom
🇬🇧The Clatterbridge Cancer Centre NHSFT, 65 Pembroke Place, Liverpool, United Kingdom
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT04609566
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸cCARE - Northern, Fresno, California, United States
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Joseph Tuscano
- Target Recruit Count
- 23
- Registration Number
- NCT04587687
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
- Conditions
- Interventions
- First Posted Date
- 2020-09-29
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT04569032
- Locations
- 🇺🇸
Stanford Cancer Center / Blood and Marrow Transplant Program, Stanford, California, United States
🇺🇸Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States
🇺🇸Johns Hopkins Medical Center, Washington, District of Columbia, United States
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 31
- Registration Number
- NCT04561206
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
- Conditions
- Interventions
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT04404283
- Locations
- 🇺🇸
Central Alabama Research, Birmingham, Alabama, United States
🇺🇸Alabama Oncology, Birmingham, Alabama, United States
🇺🇸Arizona Oncology Associates, PC - NAHOA, Goodyear, Arizona, United States
Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- University of Kansas Medical Center
- Registration Number
- NCT04334174
- Locations
- 🇺🇸
The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT04254107
- Locations
- 🇺🇸
California Research Institute, Los Angeles, California, United States
🇺🇸University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Texas Oncology - Baylor Sammons Cancer Center, Dallas, Texas, United States
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Yale University
- Registration Number
- NCT04138875
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03947255
- Locations
- 🇺🇸
Houston Methodist Cancer Center, Houston, Texas, United States
🇺🇸SCL Health Good Samaritan Medical Center Cancer Centers of Colorado, Lafayette, Colorado, United States
🇺🇸Summit Medical Group, Florham Park, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.